Hiroki Shibutani
Overview
Explore the profile of Hiroki Shibutani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koskinas K, Haner J, Ueki Y, Otsuka T, Lonborg J, Shibutani H, et al.
Circ Cardiovasc Imaging
. 2024 Nov;
17(11):e016683.
PMID: 39561225
Background: Elevated Lp(a) (lipoprotein[a]) is a risk marker for atherosclerotic disease, but the underlying mechanisms remain elusive. We examined the association of Lp(a) with changes in coronary atherosclerosis following intensive...
2.
Biccire F, Kakizaki R, Koskinas K, Ueki Y, Haner J, Shibutani H, et al.
JAMA Cardiol
. 2024 Sep;
9(12):1082-1092.
PMID: 39221516
Importance: Previous studies investigated atherosclerotic changes induced by lipid-lowering therapy in extensive coronary segments irrespective of baseline disease burden (a vessel-level approach). Objective: To investigate the effects of lipid-lowering therapy...
3.
Rexhaj E, Bar S, Soria R, Ueki Y, Haner J, Otsuka T, et al.
Atherosclerosis
. 2024 Mar;
392:117504.
PMID: 38513436
Background And Aims: The effects of protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on endothelial function as assessed by flow-mediated dilation (FMD) in patients with acute myocardial infarction (AMI) are...
4.
Rohla M, Ye S, Shibutani H, Bruno J, Otsuka T, Haner J, et al.
JACC Cardiovasc Interv
. 2024 Jan;
17(1):17-28.
PMID: 38199749
Background: Evidence to support immediate P2Y inhibitor loading in ST-segment elevation myocardial infarction (STEMI) is limited. Objectives: This study sought to compare outcomes of STEMI patients receiving immediate or delayed...
5.
Miyata T, Shibayama Y, Kawai S, Watanabe A, Shibutani H, Shibutani T, et al.
Res Vet Sci
. 2023 Nov;
166:105081.
PMID: 37979516
Dermal suctioning has been reported to yield effects similar to those of cupping therapy in humans and horses, including pain reduction, increased blood circulation, improved flexibility, and healing. However, there...
6.
Hashimoto K, Fujii K, Kawakami R, Shibutani H, Imanaka T, Kawai K, et al.
Int Heart J
. 2023 Oct;
64(5):894-900.
PMID: 37778992
Whether a nodular calcification (NC), which is the precursor to intracoronary thrombosis, is focally or diffusely distributed in the coronary tree has major implications for ongoing efforts to identify. This...
7.
Biccire F, Haner J, Losdat S, Ueki Y, Shibutani H, Otsuka T, et al.
J Am Coll Cardiol
. 2023 Aug;
82(18):1737-1747.
PMID: 37640248
Background: The frequency, characteristics, and outcomes of patients treated with high-intensity lipid-lowering therapy and showing concomitant atheroma volume reduction, lipid content reduction, and increase in fibrous cap thickness (ie, triple...
8.
Ueki Y, Haner J, Losdat S, Gargiulo G, Shibutani H, Bar S, et al.
Thromb Haemost
. 2023 Aug;
124(6):517-527.
PMID: 37595625
Objective: The effect of the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor alirocumab on platelet aggregation among patients with acute myocardial infarction (AMI) remains unknown. We aimed to explore the...
9.
Bar S, Kavaliauskaite R, Otsuka T, Ueki Y, Haner J, Siontis G, et al.
EuroIntervention
. 2023 Jun;
19(4):e286-e296.
PMID: 37341586
Background: Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on top of statins leads to plaque regression and stabilisation. The effects of PCSK9 inhibitors on coronary physiology and angiographic...
10.
Bass R, Garcia-Garcia H, Ueki Y, Holmvang L, Pedrazzini G, Roffi M, et al.
Cardiovasc Revasc Med
. 2023 Apr;
54:33-38.
PMID: 37087308
Aims: Standard manual analysis of IVUS to study the impact of anti-atherosclerotic therapies on the coronary vessel wall is done by a core laboratory (CL), the ground truth (GT). Automatic...